1-20 of 27 results for subject:Bupropion
Librarians' tools
- Search time
- 0.255 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Bupropion
- We searched for
- subject_t:Bupropion OR subject_t:"Bupropion hydrochloride" OR subject_t:Zyban OR subject_ses:420958
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask His Majesty's Government how many prescriptions for bupropion were issued in each year since 2014; and what was the annual cost to the National Health Service of those prescriptions for each of those years.
To ask His Majesty's Government how many prescriptions for bupropion were issued in each year since 2014; and what was the annual cost to the National Health Service of those prescriptions for each of those years.
The attached table shows the number of prescriptions issued for buproprion and the net ingredient cost (NIC) from 2014 to 2023, and from January to August for 2024, as this is the latest data available.
Based on the information within the Prescription Cost Analysis published statistics from the NHS Business Services Authority, there are two chemical formulations that include buproprion, those being: bupropion hydrochloride; and the combination of naltrexone and buproprion. It should also be noted that the total NIC shown in the attached table is the basic price of the prescribed medicine before discounts, dispensing costs, or fees. This includes items that have been dispensed in the community in England regardless of where prescribed.
To ask His Majesty's Government how many Yellow Card reports of sexual dysfunction and persistent sexual dysfunction the MHRA received for bupropion in each year since 2014; and what consideration NHS England has given to adding sexual dysfunction as a side effect on the patient information leaflets for bupropion.
To ask His Majesty's Government how many Yellow Card reports of sexual dysfunction and persistent sexual dysfunction the MHRA received for bupropion in each year since 2014; and what consideration NHS England has given to adding sexual dysfunction as a side effect on the patient information leaflets for bupropion.
In the United Kingdom there are two authorised products containing bupropion. The first contains bupropion hydrochloride and is prescribed to help individuals stop smoking, when they also have motivational support, for instance through a stop smoking programme. The second is a combination product containing bupropion hydrochloride and naltrexone hydrochloride, and is prescribed in obese or overweight adults to manage weight, together with a reduced calorie diet and physical exercise.
The Medicines and Healthcare products Regulatory Agency (MHRA) has received three Yellow Card reports of sexual dysfunction related reactions suspected to be associated with bupropion hydrochloride, the single constituent, and one Yellow Card report of sexual dysfunction for the combination product, bupropion hydrochloride and naltrexone hydrochloride, between 1 January 2014 and 29 October 2024.
The following table shows the number of suspected Yellow Card reports of sexual dysfunction related reactions and bupropion containing products received by the MHRA between 2014 and 2024:
Year | Reports of sexual dysfunction single constituent bupropion | Reports of sexual dysfunction combination product bupropion and naltrexone |
2014 | 0 | 0 |
2015 | 0 | 0 |
2016 | 0 | 0 |
2017 | 0 | 0 |
2018 | 0 | 0 |
2019 | 0 | 0 |
2020 | 1 | 1 |
2021 | 0 | 0 |
2022 | 1 | 0 |
2023 | 0 | 0 |
2024 | 1 | 0 |
Source: data provided by the MHRA.
Note: the data includes reactions grouped under the Medical Dictionary for Regulatory Activities’ (MedDRA) Higher Level Terms: erection and ejaculation conditions and disorders; orgasmic disorders and disturbances; sexual and gender identity disorders NEC; sexual arousal disorders; sexual desire disorders; sexual dysfunction NEC; sexual function and fertility disorders NEC; and spermatogenesis and semen disorders.
Persistent sexual dysfunction does not represent a specific medical condition, so this precise term is not a category available to undertake a structured search of the MHRA’s Adverse Drug Reaction database, and would rely on manual assessment of individual cases. The structured data field search terms are drawn from the regulatory drugs dictionary, MedDRA, or from terms adopted in clinical coding guidance such as the Diagnostic and Statistical Manual of Mental Disorders or the International Classification of Diseases.
It is important to note that the inclusion of a particular report on the MHRA’s system does not necessarily mean that the adverse reactions reported have been caused by the suspect drug. Additionally, the number of reports received should not be used as a basis for determining the incidence of a reaction, as neither the total number of reactions occurring, nor the number of patients using the drug, is known.
The product information, which includes the patient information leaflet, for single constituent bupropion reflects the data currently available, and does not include sexual dysfunction as a possible side effect. The product information for the combination bupropion and naltrexone product contains the terms loss of libido, libido disorder, and erectile dysfunction. As with other medicines, the safety of bupropion is kept under review by the MHRA, and consideration will be given to any emerging evidence on this issue.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of (a) Lisdexamfetamine and (b) Bupropion Hydrochloride.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of (a) Lisdexamfetamine and (b) Bupropion Hydrochloride.
The Department is aware of intermittent supply disruptions affecting Elvanse (lisdexamfetamine) capsules. We continue to work with the respective manufacturer to ensure continuous supply is resumed quickly. However, we can confirm that Elvanse 20mg, 40mg and 60mg capsules are currently in stock and pharmacies should be able to obtain stock via normal wholesaler routes.
We are also aware of a shortage with Bupropion. The resupply date of this product is still to be confirmed. We have issued comprehensive management guidance to healthcare professionals on this shortage in December 2022. Guidance advises on the management of patients who require this medication for both licensed and off-label indications. Clinicians can advise patients on suitable alternative products, and other management options that can be considered. This includes unlicensed bupropion 150mg modified release tablets which have been sourced.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 February 2023 to Question 147126 on Bupropion, whether he has made a recent assessment of the adequacy of the availability of bupropion; if he will publish guidance for people using bupropion for ADHD...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 February 2023 to Question 147126 on Bupropion, whether he has made a recent assessment of the adequacy of the availability of bupropion; if he will publish guidance for people using bupropion for ADHD...
The Department is aware of a shortage with Bupropion.
We issued comprehensive management guidance to healthcare professionals on this shortage in December 2022. The guidance advises on the management of patients who require this medication for both licensed and off-label indications. Clinicians can advise patients on suitable alternative products, and other management options that can be considered. This includes unlicensed Bupropion 150 milligram modified release tablets which have been sourced.
To ask the Secretary of State for Health and Social Care, what steps his Department are taking to improve the supply of Bupropion.
To ask the Secretary of State for Health and Social Care, what steps his Department are taking to improve the supply of Bupropion.
The Department is aware of a shortage with bupropion with a resupply date to be confirmed. We issued management guidance to the National Health Service on this shortage on 1 December 2022 advising on the management of patients who require this medication for both licensed and off-label indications. Clinicians can advise on suitable alternative products, and other management options that can be considered, including unlicensed bupropion tablets which have been sourced.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of Bupropion.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of Bupropion.
The Department is aware of a shortage with Bupropion. The resupply date of this product is to be confirmed by the manufacturer. We have issued comprehensive management guidance to healthcare professionals on this shortage in December 2022.
To ask the Secretary of State for Health and Social Care, how many prescriptions of Zyban (bupropion hydrochloride) were dispensed by (a) the NHS and (b) community pharmacies in each of the last three years.
To ask the Secretary of State for Health and Social Care, how many prescriptions of Zyban (bupropion hydrochloride) were dispensed by (a) the NHS and (b) community pharmacies in each of the last three years.
NHS Digital reports that it does not hold the prescription level data requested. NHS Digital holds data about prescription items dispensed by doctors and community pharmacies in England which is available in the following table.
Year | Chemical | Dispensed by dispensing doctors | Dispensed by community pharmacies | All dispensing in the community |
2015 | Bupropion Hydrochloride | 1,130 | 20,701 | 21,831 |
2016 | Bupropion Hydrochloride | 1,110 | 21,231 | 22,341 |
2017 | Bupropion Hydrochloride | 1,084 | 22,254 | 23,338 |
Source: Prescription Cost Analysis, NHS Digital
NHS Digital does not hold data on drugs dispensed in hospitals, including mental health trusts, or private prescriptions.
To ask the Secretary of State for Health, how many prescriptions were issued for bupropion in each year since 2001.
To ask the Secretary of State for Health, how many prescriptions were issued for bupropion in each year since 2001.
Information is not collected centrally on the numbers of prescriptions issued. However, information is available on the number of bupropion hydrochloride prescription items dispensed.
Number of bupropion hydrochloride prescription items written in the United Kingdom and dispensed in the community in England - 2001 to 2014 | |
Year | Items (000’s) |
2001 | 298.8 |
2002 | 131.0 |
2003 | 111.8 |
2004 | 136.8 |
2005 | 131.9 |
2006 | 116.9 |
2007 | 129.9 |
2008 | 62.1 |
2009 | 51.1 |
2010 | 39.3 |
2011 | 32.3 |
2012 | 27.8 |
2013 | 23.7 |
2014 | 22.0 |
Source: Prescription Cost Analysis provided by the Health and Social Care Information Centre
To ask the Secretary of State for Health, what guidance he has given to general practitioners regarding possible side effects of use of the drug Zyban; if he will make a statement on yellow card reports received in connection with use of the drug Zyban. - Inc figures.
To ask the Secretary of State for Health, what guidance he has given to general practitioners regarding possible side effects of use of the drug Zyban; if he will make a statement on yellow card reports received in connection with use of the drug Zyban. - Inc figures.
To ask the Secretary of State for Health, whether the review of selective serotonin reuptake inhibitors and related anti-depressants includes an assessment of possible risks that such drugs may induce violent and dangerous behaviour in some users; whether mirtazapine and bupropion are included in the review of selective serotonin reuptake...
To ask the Secretary of State for Health, whether the review of selective serotonin reuptake inhibitors and related anti-depressants includes an assessment of possible risks that such drugs may induce violent and dangerous behaviour in some users; whether mirtazapine and bupropion are included in the review of selective serotonin reuptake...
To ask the Secretary of State for Health, whether the review of selective serotonin reuptake inhibitor and related antidepressants includes investigation of whether such drugs may induce violent and dangerous behaviour in some users; whether the drugs (a) mirtazapine and (b) bupropion were included in the review of selective serotonin...
To ask the Secretary of State for Health, whether the review of selective serotonin reuptake inhibitor and related antidepressants includes investigation of whether such drugs may induce violent and dangerous behaviour in some users; whether the drugs (a) mirtazapine and (b) bupropion were included in the review of selective serotonin...
To ask the Secretary of State for Health, whether the drugs (a) mirtzapine and (b) bupropion are included in the review of selective serotonin reuptake inhibitors antidepressants and related drugs; and whether either carries a risk of inducing suicidal behaviour comparable with that of the drugs now under review.
To ask the Secretary of State for Health, whether the drugs (a) mirtzapine and (b) bupropion are included in the review of selective serotonin reuptake inhibitors antidepressants and related drugs; and whether either carries a risk of inducing suicidal behaviour comparable with that of the drugs now under review.
Lords debate on unstarred question on the therapies available to help people to stop smoking.
Lords debate on unstarred question on the therapies available to help people to stop smoking.
To ask the Secretary of State for Health, what plans there are to extend the use of Zyban (a) on prescription-only and (b) over the counter.
To ask the Secretary of State for Health, what plans there are to extend the use of Zyban (a) on prescription-only and (b) over the counter.
Summary of CSM consideration of and regulatory action taken with Zyban (bupropion). DH/MCA. 2003.
Summary of CSM consideration of and regulatory action taken with Zyban (bupropion). DH/MCA. 2003.
To ask the Secretary of State for Health, if he will place in the Library (a) submissions to, (b) briefing documents used by and (c) risk analysis carried out by the MCA in its consideration of Zyban in the last two years. (Summary in Library Dep 03/439).
To ask the Secretary of State for Health, if he will place in the Library (a) submissions to, (b) briefing documents used by and (c) risk analysis carried out by the MCA in its consideration of Zyban in the last two years. (Summary in Library Dep 03/439).
To ask the Secretary of State for Health, what assessment he has made (i) on the long term efficacy of (a) Zyban and (b) nicotine replacement therapies (i) in the UK and (ii) in other Council of Europe countries in reducing the number of regular smokers. - Inc fact that...
To ask the Secretary of State for Health, what assessment he has made (i) on the long term efficacy of (a) Zyban and (b) nicotine replacement therapies (i) in the UK and (ii) in other Council of Europe countries in reducing the number of regular smokers. - Inc fact that...
To ask the Secretary of State for Health, what his estimate is of the likely (a) fatal and (b) non-fatal side effects of Zyban if used for six months. - Inc figures.
To ask the Secretary of State for Health, what his estimate is of the likely (a) fatal and (b) non-fatal side effects of Zyban if used for six months. - Inc figures.
To ask the Secretary of State for Health, what his estimate is of the likely changes that will take place in the next five year totals of (a) male and (b) female smokers as a result of the ban on tobacco advertising and the future use of nicotine replacement therapies...
To ask the Secretary of State for Health, what his estimate is of the likely changes that will take place in the next five year totals of (a) male and (b) female smokers as a result of the ban on tobacco advertising and the future use of nicotine replacement therapies...
To ask the Secretary of State for Health, how many prescriptions for Zymau have been issued in each month since the drug was licensed, broken down by health authority.
To ask the Secretary of State for Health, how many prescriptions for Zymau have been issued in each month since the drug was licensed, broken down by health authority.